CLINICAL TRIALS PROFILE FOR CARDENE IN 4.8% DEXTROSE IN PLASTIC CONTAINER

All Clinical Trials for CARDENE IN 4.8% DEXTROSE IN PLASTIC CONTAINER

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00325793 ↗	IV Double and Triple Concentrated Nicardipine for Stroke and ICH	Unknown status	PDL BioPharma, Inc.	Phase 4	2004-01-01	Hypertension (high blood pressure) can often cause neurological worsening in patients with stroke, intracerebral hemorrhage and subarachnoid hemorrhage. Intravenous infusion of nicardipine (Cardene) for control of hypertension is FDA approved. The disadvantage of Nicardipine IV drip is the relative large volume of fluid needed (up to 150 cc/hr). The purpose of this study is to evaluate safety and efficacy of double or triple concentrated peripheral intravenous (IV) Nicardipine.
NCT00325793 ↗	IV Double and Triple Concentrated Nicardipine for Stroke and ICH	Unknown status	OSF Healthcare System	Phase 4	2004-01-01	Hypertension (high blood pressure) can often cause neurological worsening in patients with stroke, intracerebral hemorrhage and subarachnoid hemorrhage. Intravenous infusion of nicardipine (Cardene) for control of hypertension is FDA approved. The disadvantage of Nicardipine IV drip is the relative large volume of fluid needed (up to 150 cc/hr). The purpose of this study is to evaluate safety and efficacy of double or triple concentrated peripheral intravenous (IV) Nicardipine.
NCT00528827 ↗	A Randomized, Double-blinded, Placebo-controlled, Dose-ranging Study of Cardene® I.V. in Pediatric Subjects With Hypertension	Withdrawn	Facet Biotech	Phase 2	2007-09-01	To define the relationship between Cardene I.V. dose, serum concentrations, and blood pressure reduction in pediatric subjects with hypertension.
NCT00765648 ↗	Evaluation of Intravenous Cardene(Nicardipine)and Labetalol Use in the Emergency Department	Completed	EKR Therapeutics, Inc	Phase 4	2008-10-01	The purpose of this study is to compare the safety and efficacy of Cardene I.V. to labetalol administered intravenously for the management of hypertension in the emergency department setting.
NCT00765648 ↗	Evaluation of Intravenous Cardene(Nicardipine)and Labetalol Use in the Emergency Department	Completed	The Cleveland Clinic	Phase 4	2008-10-01	The purpose of this study is to compare the safety and efficacy of Cardene I.V. to labetalol administered intravenously for the management of hypertension in the emergency department setting.

Clinical Trial Conditions for CARDENE IN 4.8% DEXTROSE IN PLASTIC CONTAINER

Condition Name

Condition Name for CARDENE IN 4.8% DEXTROSE IN PLASTIC CONTAINER
Intervention	Trials
Hypertension	3
Cerebral Vasospasm	2
Hypotensive Anesthesia	1
Nontraumatic Intracerebral Hemorrhage, Multiple Localized	1

Condition MeSH

Condition MeSH for CARDENE IN 4.8% DEXTROSE IN PLASTIC CONTAINER
Intervention	Trials
Hypertension	3
Vasospasm, Intracranial	2
Cerebral Hemorrhage	2
Emergencies	1

Clinical Trial Locations for CARDENE IN 4.8% DEXTROSE IN PLASTIC CONTAINER

Trials by Country

Trials by Country for CARDENE IN 4.8% DEXTROSE IN PLASTIC CONTAINER
Location	Trials
United States	18
Switzerland	1

Trials by US State

Trials by US State for CARDENE IN 4.8% DEXTROSE IN PLASTIC CONTAINER
Location	Trials
Illinois	2
Massachusetts	2
Texas	2
Ohio	2
Florida	2

Clinical Trial Progress for CARDENE IN 4.8% DEXTROSE IN PLASTIC CONTAINER

Clinical Trial Phase

Clinical Trial Phase for CARDENE IN 4.8% DEXTROSE IN PLASTIC CONTAINER
Clinical Trial Phase	Trials
Phase 4	6
Phase 2	3

Clinical Trial Status

Clinical Trial Status for CARDENE IN 4.8% DEXTROSE IN PLASTIC CONTAINER
Clinical Trial Phase	Trials
Withdrawn	3
Recruiting	2
Terminated	1

Clinical Trial Sponsors for CARDENE IN 4.8% DEXTROSE IN PLASTIC CONTAINER

Sponsor Name

Sponsor Name for CARDENE IN 4.8% DEXTROSE IN PLASTIC CONTAINER
Sponsor	Trials
Vanderbilt University Medical Center	2
Columbia University	1
University of Michigan	1

Sponsor Type

Sponsor Type for CARDENE IN 4.8% DEXTROSE IN PLASTIC CONTAINER
Sponsor	Trials
Other	22
Industry	4
NIH	1